Peginesatide (INN/USAN trade name Omontys formerly Hematide) developed by Affymax and Takeda is an erythropoietic agent a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.
ATC prefix
B03
ATC suffix
XA04
CAS number
913976-27-9
CAS supplemental
(acetate)
ChEBI
66889
IUPAC name
Poly(oxy-12-ethanediyl) α-hydro-ω-methoxy- diester with 21N621'N6-[(N2N6-dicarboxy-(L)-lysyl-β-alanyl)imino]bis(1-oxo-21-ethanediyl)bis[N-acetylglycylglycyl-(L)-leucyl-(L)-tyrosyl-(L)-alanyl-(L)-cysteinyl-(L)-histidyl-(L)-methionylglycyl-(L)-prolyl-(L)-isoleucyl-(L)-threonyl-3-(1-naphthalenyl)-(L)-alanyl-(L)-valyl-(L)-cysteinyl-(L)-glutaminyl-(L)-prolyl-(L)-leucyl-(L)-arginyl-N-methylglycyl-(L)-lysinamide] cyclic (6→15)(6'→15')-bis(disulfide)
This page contains content from the copyrighted Wikipedia article "Peginesatide"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.